Development of non-invasive biomarker discovery and diagnostics approach for bladder cancer based on urine proteome and phosphoproteome
Award amount
$224,999Program and phase
SBIR · Phase IAward year
2019Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- TYMORA ANALYTICAL OPERATIONS LLC
- Proposal award date
- 2019-09-01
- Contract end date
- 2020-08-31
- UEI
- ZFFZKDYTF5Q9
- Solicitation number
- PA18-574
- Topic code
- 102
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Validation and clinicaldevelopment of plasma EV protein biomarkers for minimally-invasive detection of Alzheimersdisease
- Development of lavage EV protein biomarkers for minimally-invasive detection of endometrial cancer
- Development of companion diagnostics for dasatinib-based personalized therapy for T-ALL
- Developing EV surface proteins as biosignatures for Alzheimer's disease (AD)
- Development of non-invasive biomarker discovery and diagnostics approach for bladder cancer based on urine proteome and phosphoproteome
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- MiREA, a mHealth intervention to Reduce Health Disparities by Improving Equitable Access to Mandated College Students with Problematic Alcohol and Marijuana Use
- Modex, a cloud-based, centralized health economic model marketplace to reduce costs and enhance equity in cancer
- Precision screening in self-collected samples to reduce cervical cancer disparities among Latinas
- Allogeneic cell and gene therapy for neuroendocrine tumors
- Nanoparticle formulation of Mediator kinase inhibitor for the treatment of peritoneal ovarian cancer
Research funding history
17 SBIR/STTR records share this UEI (2011–2024). Reported award amounts total $7,866,983. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, National Science Foundation